Cancer is still the leading cause of death globally. The approval of the therapeutic use of
monoclonal antibodies against immune checkpoint molecules, notably those that target the …

The application of immune checkpoint inhibitors (ICIs) has markedly enhanced the treatment
of hepatocellular carcinoma (HCC), and HCC patients who respond to ICIs have shown …

Until the advent of immune checkpoint inhibitors (ICIs), definitive radiotherapy (RT)
concurrently with chemotherapy was recommended for unresectable, locally advanced non …

Immune checkpoint inhibition (ICI) therapies have reshaped the therapeutic landscape in
lung cancer management, providing first-time improvements in patient response, prognosis …

Lung cancer is a leading cause of cancer-related deaths, and the most common type is lung
adenocarcinoma (LUAD). LUAD is frequently diagnosed in people who never smoked …

Introduction The effect of platinum-based chemotherapy (Chem.) and second-or multiple-
line immune checkpoint PD-1 blocking therapy by Nivolumab or Pembrolizumab (ICI) was …

Background Osimertinib is a recommended treatment for advanced non–small-cell lung
cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation and as adjuvant …

Opinion statement Ovarian carcinosarcoma (OCS), also known as a malignant mixed
Müllerian tumour (MMMT), is a rare and aggressive form of cancer that accounts for less …

Tumor microenvironment (TME) cells orchestrate an immunosuppressive milieu that
supports cancer cell proliferation. Tumor-associated neutrophils (TANs) have gained …

Toll-like receptors (TLRs) are natural initial triggers of innate and adaptive immune
responses. With the advent of cancer immunotherapy, nucleic acids engineered as ligands …